Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SULTAN trial in unresectable liver-only colorectal liver metastases
2016-001493-15Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil, folinic acid, cetuximab and 2 more in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Unicancer. Primary endpoint: Curative-intent resection/ablation rate. Started Oct 2017; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acidcetuximab
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2016-001493-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001493-15.